Trial Profile
An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Acronyms SILVER
- 24 Apr 2015 New trial record